World APS Day: Shining a Light on a Silent but Life-Threatening Autoimmune Disorder
The APS Foundation of America has shared an important update on their official X page in recognition of World APS Day. The post emphasizes the urgent need to raise awareness about Antiphospholipid Syndrome (APS)—an incurable, life-threatening autoimmune disorder that increases the risk of dangerous blood clots.
“Today is World APS Day, the global awareness campaign to raise awareness of Antiphospholipid Syndrome and its impact on our lives.
APS is an incurable, life-threatening autoimmune condition that causes the blood to clot.”
What is APS?
APS occurs when the immune system mistakenly produces antibodies that target phospholipids—critical components of cell membranes—leading to an increased risk of:
- Deep vein thrombosis (DVT)
- Pulmonary embolism
- Stroke
- Recurrent miscarriage
- Catastrophic multiorgan thrombosis in severe cases
Despite its profound clinical impact, APS remains underdiagnosed and misunderstood.
Hemostasis Today proudly joins the global movement to raise awareness, promote early diagnosis, and support ongoing research into this devastating condition. As we commemorate World APS Day, we stand with patients, families, and advocates in calling for increased education, improved testing, and more targeted therapies.
Let today be a reminder: Clots can kill, but knowledge can save lives.
Follow us on Hemostasis Today for expert insights, clinical updates, and patient stories throughout APS Awareness Month.
-
Sep 18, 2025, 06:50Fetal Hereditary TTP Featured in NEJM – Senior Author Nishant Rajendra Tiwari
-
Sep 17, 2025, 10:54Mitapivat Boosts ATP in Red Cells: Dr. William Aird on New Hope for Hemolytic Disorder
-
Sep 17, 2025, 08:16Superficial Vein Thrombosis Management: John Fanikos Shares Latest Review
-
Sep 17, 2025, 07:00Maha Othman - ''BIC 2025 is Without a Doubt a Remarkable Scientific Event — and I’m Excited for What Lies Ahead!''
-
Sep 16, 2025, 11:17Glenn Pierce: WHO Issues a Biannual Essential Medicines List
-
Sep 18, 2025, 07:00Rishabh Singh on NEJM Letter: FVIII Aurora Mutation Shows Increased Activity and Reduced APC Response
-
Sep 18, 2025, 02:25Flora Peyvandi Highlights 'Inflammatory Memory of Stem Cells' – New Insights for Hematologic Diseases
-
Sep 17, 2025, 16:32Endovascular Today: Dr. Eric Secemsky Analyzes Impact of Paclitaxel Pause on Peripheral Artery Disease Care
-
Sep 17, 2025, 16:28Haemnet Showcases Research on Severe Haemophilia A Patients Adapting to Emicizumab Therapy
-
Sep 17, 2025, 16:19Todd Villines: Coronary Artery Disease - A BIG Movement to Change
-
Sep 16, 2025, 14:59A New Era in Antiplatelet Therapy for CABG?
-
Sep 16, 2025, 07:44Artificial Blood Breakthrough in Japan: Long Shelf Life, No Type Matching, and a Purple Future
-
Sep 16, 2025, 02:44Wolfgang Miesbach Highlights First Inhibitor Case After Hemophilia A Gene Therapy (Giroctocogene Fitelparvovec)
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 18, 2025, 06:34'A New Era in Mechanical Thrombectomy?' – Sripal Bangalore Highlights SYMPHONY-PE IDE Study
-
Sep 17, 2025, 10:49Living with Glanzmann Thrombasthenia․ Eliza VanZweden’s Story of Resilience and Advocacy
-
Sep 17, 2025, 10:22Abdul Mannan: Turning Medical Podcasts into Active Learning with Structured Tools
-
Sep 17, 2025, 09:43Global Blood Supply Under Threat: David McIntosh Calls for Action to Support Transfusion Services
-
Sep 17, 2025, 09:08Coronary Arteries, Pericardial Cavity, and the Hidden Danger of Cardiac Tamponade During PCI-By Ahmed Ata